– UK, London – ValiRx Plc (LON: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today announced the appointment of Luke Cairns to its Board as an Independent Non-Executive Director, subject to regulatory due diligence.
“Luke will be an excellent addition to the Board of ValiRx given his extensive experience in small companies, corporate finance and corporate governance. He will provide help and advice across all areas of the business but particularly in respect of ValiRx as a quoted company. His independent and objective views will help ensure continued progress of our strategic plans.” said Board Chair, Dr. Kevin Cox.
About Luke Cairns
Luke Cairns is an experienced corporate finance professional with over 20 years of working with SMEs as both an adviser and director. He was previously Head of Corporate Finance and Joint Managing Director at Northland Capital Partners Limited, an AIM Nominated Adviser and broker firm, and has worked with many companies across several sectors and regions on a wide range of transactions, including IPOs, secondary fundraisings, corporate restructurings, and takeovers.
Luke Cairns set up his consultancy working with growth companies and family offices and now sits on several private and public boards.
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, to achieve a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx’s portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialization.
SOURCE: https://www.valirx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
